Investor Presentaiton
3
Am I responding to
therapy? Should I
switch therapy?
High precision of tumor fraction
estimates is attained in
epigenomic assay based on
1,000s of alterations assessed
GUARDANT 360 Response
GUARDANTREVEAL
INVESTOR 20
DAY 23
3X higher precision¹ of epigenomics enables to see therapy response
clearer and make better patient management decisions
Tumor Fraction, %
0.05
0.10
0.15
0.20
0.25
Genomic Assessment
Before
Treatment
Point Estimate
Confidence interval
No change
On Treatment
Tumor Fraction, %
0.05 0.10
0.15
0.20 0.25
Epigenomic Assessment
Point Estimate
Confidence interval
Significant change
Before
Treatment
On Treatment
GUARDANT™
Response in early
phase trials
Surrogate Endpoint
Development
Switching therapy based
on lack of response
1 3X higher precision estimated in comparison to response tracking with 3 somatic mutations for a representative sample at 0.1% tumor fraction and
typical input amount, based on internal data
35View entire presentation